期刊文献+

胸腔积液的病因诊断现状 被引量:4

在线阅读 下载PDF
导出
摘要 胸腔积液是由于全身或局部病变破坏了胸膜腔内液体滤过与吸收的动态平衡导致胸膜腔内液体形成过快或吸收过缓所产生,是临床上一种常见病征,可原发于胸膜疾病,亦可继发于肺、纵隔、食管、心、肝、脾、肾、卵巢、全身结缔组织病、血液系统疾病等,及时正确的病因诊断对患者下一步治疗及预后具有十分重要的意义。
出处 《临床内科杂志》 CAS 2015年第10期653-656,共4页 Journal of Clinical Internal Medicine
作者简介 通讯作者:施焕中,E-mail:shihuanzhong@sina.com
  • 相关文献

参考文献29

  • 1Heffner JE. Diagnosis and management of malignant pleural effusions [ J ]. Respirology ,2008,13 ( 1 ) :5-20.
  • 2Hooper C, Lee YC, Maskell N, et al. Investigation of a unilateral pleural effusion in adults: British Thoracic Society: Plueral Disease Guideline 2010[J]. Thorax ,2010,65 (2) : 114-117.
  • 3王兵,赵彪,颜琳琳,侯炜.恶性胸腔积液的影像学诊断研究进展[J].中国医药,2013,8(8):1197-1198. 被引量:2
  • 4Duysinx B, Nguyen D, Louis R, et al. Evaluation of pleural disease with 18-fluorodeoxyglucose positron emission tomography imaging [ J ]. Chest,2004,125 ( 2 ) :489-493.
  • 5Toaff JS, Metser U, Goqfried M, et al. Differentiation between malignant and benign pleural effusion in patients with extra-pleural primary malig- nancies:assessment with positron emission tomography-computed tomo- graphy[ J]. Invest Radial,2005,40(4) :204-209.
  • 6王彩彩,田光,徐红霞,姜毅,黄燕,路聪哲,段蕴铀.肺结节病并胸腔积液诊治分析[J].中国医药,2013,8(5):620-621. 被引量:7
  • 7王元元,梁永杰,王凯玲,韩杨,任涛.肺腺癌伴嗜酸粒细胞性胸腔积液一例[J].临床内科杂志,2013,30(12):835-836. 被引量:1
  • 8Light RW, Macgregor MI, Luchsinger PC, et al. Pleural effusions : the diagnostic separation of transudates andexudates [ J ]. Ann-Intern Med,1972,77(4) :507-516.
  • 9Romero S, Martinez A, Hemandez L, et al. Light, s criteria revisited consistency and comparison with new proposed alternative criteria for separating pleural transudates from exudates[J]. Respiration,2000,67 (1):18-23.
  • 10Liang QL, Shi HZ, Wang K, et al. Diagnostic accuracy of adenosine deaminase in tuberculous pleurisy : a meta-analysis E J J- Respir Med, 2008,102 ( 5 ) : 744 -754.

二级参考文献34

共引文献7

同被引文献63

  • 1周江,罗世林,张仕国.包裹性胸腔积液42例临床分析[J].实用医院临床杂志,2010,7(4):135-136. 被引量:3
  • 2Stinchcombe TE, Socinski MA. Current treatments for advanced stage non-small cell lung cancer[ J]. Proc Am Thorac Soc, 2009, 6 (2) :233-241. DOI : 10. 1513/pats. 200809-110LC.
  • 3Goldstraw P, Crowley J, Chansky K, et al. The IASLC lung canc- er staging project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classi- fication of malignant tumours [ J ]. J Thorac Oncol, 2007,2 (8) : 706-714. DOI : 10. 1097/JTO. 0b013e31812f3cl a.
  • 4Witkin SS. Heat shock protein expression and immunity: rele- vance to gynecologic oncology[ J]. Eur J Gynaecol Oncol, 2001, 22(4) :249-256.
  • 5Maloney A, Workman P. HSP90 as a new therapeutic target for cancer therapy: the story unfolds [J]. Expert Opin Biol Ther, 2002,2( 1 ) :3-24. DOI: 10. 1517/14712598.2.1.3.
  • 6Grammatikakis N, Vuhur A, Ramana CV, et al. The role of Hsp90N, a new member of the Hsp90 family, in signal transduction and neoplastic transformation [ J ]. J Biol Chem, 2002,277 ( 10 ) : 8312-8320. DOI: 10. 1074/jbc. M109200200.
  • 7Shimamura T, Perera SA, Foley KP, et al. Ganetespib (STA- 9090), a nongeldanamycin HSP90 inhibitor, has potent antitumoractivity in in vitro and in vivo models of non-small cell lung cancer[ J ]. Clin Cancer Res, 2012,18 ( 18 ) : 4973-4985. DOI : 10. 1158/1078-0432. CCR-I 1-2967.
  • 8Clive AO, Kahan BC, Hooper CE, et al. Predicting survival in malignant pleural effusion: development and validation of the LENT prognostic score [ J]. Thorax, 2014,69 ( 12 ) : 1098-1104. DOI : 10.1136/thoraxjnl-2014-205285.
  • 9Hong DS, Banerji U, Tavana B, et al. Targeting the molecular chaperone heat shock protein 90 (HSP90) : lessons learned and future directions [ J ]. Cancer Treat Rev, 2013,39 ( 4 ) : 375-387. DOI: 10. 1016/j. ctrv. 2012.10. 001.
  • 10施一江,赵玫,徐先发,乔绘红,黄常志.主要人热休克蛋白在癌组织及癌旁正常组织中表达水平的比较研究[J].中华肿瘤杂志,1998,20(4):277-279. 被引量:47

引证文献4

二级引证文献25

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部